Centiva Capital LP Has $2.49 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Centiva Capital LP lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 43.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,509 shares of the medical research company’s stock after selling 8,026 shares during the period. Centiva Capital LP’s holdings in IQVIA were worth $2,490,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Canada Pension Plan Investment Board raised its holdings in shares of IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after acquiring an additional 211,653 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after acquiring an additional 86,870 shares in the last quarter. FMR LLC raised its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. Impax Asset Management Group plc raised its holdings in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of IQVIA by 0.8% during the second quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock worth $320,170,000 after acquiring an additional 11,715 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. Barclays cut their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Leerink Partners restated an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. BTIG Research cut their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Truist Financial cut their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Up 0.5 %

IQV stock opened at $201.79 on Tuesday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a market cap of $36.62 billion, a PE ratio of 26.48, a price-to-earnings-growth ratio of 2.07 and a beta of 1.49. The business’s 50-day simple moving average is $217.89 and its 200 day simple moving average is $225.88. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.